Parabilis Medicines has initiated a dose-ranging clinical study of zolucatetide, its lead investigational drug, targeting familial adenomatous polyposis (FAP), a genetic condition causing precancerous polyps. Zolucatetide directly inhibits the β-catenin:TCF interaction, addressing the underlying biology of FAP driven by APC mutations. Early data show significant reductions in polyp burden and good safety, supporting further development. Additional data from ongoing trials are expected in early 2027, with plans to define dosing for registrational studies.
The Parabilis Medicines clinical study of zolucatetide is the subject here, with Pluang market data providing context. For readers following the health sector, 103 of 150 priced US health stocks rose and 40 fell today. Notable movers include NUWE at USD 0.60 with a 3.53% decline and 64% buy order activity, CLPT at USD 10.14 with a 3.36% gain and 100% buy order activity, and GH at USD 158.20 with a 2.40% decline and 100% buy order activity. This data is as of Oct 14, 2026 18:11 WIB.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
